In prostate cancer, systemic administration of a truncated recombinant form (GLIPR1-ΔTM) has demonstrated potent anti-tumor effects, including induction of ROS-mediated apoptosis and suppression of oncogenic c-Myc signaling. Here, GLIPR1 is linked to prostate carcinoma.